A360
Key Takeaways✦ Atlas AI
01
Researchers identified BEX2 as a protein that regulates colorectal cancer cell 'stemness,' with lower levels linked to aggressive tumors and reduced disease-free survival, indicating its crucial role in cancer progression.
02
BEX2 suppresses the Hedgehog signaling pathway by degrading MCL1, thereby inhibiting cancer stem cell activity and offering a potential therapeutic strategy to prevent colorectal cancer relapse by targeting treatment-resistant cells.
03
This novel approach, supported by patient data and lab studies, suggests restoring BEX2 or inhibiting MCL1/Hedgehog signaling could combat recurrence, though further research is needed to validate BEX2 as a clinical biomarker or therapeutic target.
Atlas AI
A protein called BEX2 may help restrain “stem-like” behavior in colorectal cancer cells, a trait associated with treatment resistance and relapse, according to research highlighted by Medical News Today.
The report describes findings suggesting that tumors with lower BEX2 levels tend to show more aggressive features and are linked to poorer disease-free survival. In laboratory and animal studies, BEX2 appeared to limit cancer cells’ ability to self-renew, spread, and survive treatment.
How BEX2 may affect tumor behavior
Researchers propose that BEX2 promotes the degradation of MCL1, a molecule that supports cancer cell survival and is often overexpressed in colorectal cancer. By helping break down MCL1, BEX2 may reduce activity in the Hedgehog signaling pathway.
Hedgehog signaling is described as a driver of cancer stem cell activity and is associated with treatment resistance and recurrence. When BEX2 is low or absent, MCL1 becomes more stable, which may activate Hedgehog signaling and enhance stem-like traits.
Potential therapeutic strategy
The study suggests that targeting this BEX2–MCL1–Hedgehog axis could be a possible approach to reduce relapse risk. Strategies discussed include restoring BEX2 function or inhibiting MCL1 or Hedgehog signaling to help eliminate treatment-resistant, stem-like cancer cells.
Evidence and next steps
The findings are supported by analyses of patient datasets, cell and laboratory experiments, and mouse models. Across these analyses, lower BEX2 levels were observed in colorectal cancer tissue compared with normal tissue and were associated with poorer outcomes.
The report notes that further research is still needed to validate BEX2 as a clinical biomarker or a therapeutic target.
